- Home
- MCRB vs LWLG Comparison
MCRB vs LWLG Comparison
Compare MCRB & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- LWLG
- Stock Information
- Founded
- MCRB 2010
- LWLG 1991
- Country
- MCRB United States
- LWLG United States
- Employees
- MCRB N/A
- LWLG N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- LWLG Containers/Packaging
- Sector
- MCRB Health Care
- LWLG Industrials
- Exchange
- MCRB Nasdaq
- LWLG Nasdaq
- Market Cap
- MCRB 125.7M
- LWLG 126.0M
- IPO Year
- MCRB 2015
- LWLG N/A
- Fundamental
- Price
- MCRB $19.44
- LWLG $2.39
- Analyst Decision
- MCRB Hold
- LWLG
- Analyst Count
- MCRB 4
- LWLG 0
- Target Price
- MCRB $73.67
- LWLG N/A
- AVG Volume (30 Days)
- MCRB 126.4K
- LWLG 1.1M
- Earning Date
- MCRB 08-06-2025
- LWLG 08-14-2025
- Dividend Yield
- MCRB N/A
- LWLG N/A
- EPS Growth
- MCRB N/A
- LWLG N/A
- EPS
- MCRB 10.22
- LWLG N/A
- Revenue
- MCRB N/A
- LWLG $94,355.00
- Revenue This Year
- MCRB N/A
- LWLG N/A
- Revenue Next Year
- MCRB N/A
- LWLG N/A
- P/E Ratio
- MCRB $1.98
- LWLG N/A
- Revenue Growth
- MCRB N/A
- LWLG 4.52
- 52 Week Low
- MCRB $6.53
- LWLG $0.79
- 52 Week High
- MCRB $26.40
- LWLG $4.23
- Technical
- Relative Strength Index (RSI)
- MCRB 69.44
- LWLG 63.74
- Support Level
- MCRB $15.79
- LWLG $1.99
- Resistance Level
- MCRB $18.12
- LWLG $2.32
- Average True Range (ATR)
- MCRB 1.51
- LWLG 0.14
- MACD
- MCRB 0.28
- LWLG -0.02
- Stochastic Oscillator
- MCRB 97.69
- LWLG 90.93
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.